Howard I Maibach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5631936/publications.pdf

Version: 2024-02-01

276 papers

7,808 citations

45 h-index 76900 **74** g-index

293 all docs

293 docs citations

times ranked

293

5209 citing authors

#	Article	IF	CITATIONS
1	Did human evolution in skin of color enhance the TEWL barrier?. Archives of Dermatological Research, 2022, 314, 121-132.	1.9	9
2	Unbearable transepidermal water loss (TEWL) experimental variability: why?. Archives of Dermatological Research, 2022, 314, 99-119.	1.9	11
3	Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016. Journal of the American Academy of Dermatology, 2022, 86, 782-790.	1.2	16
4	Patch Testing to Carvone: North American Contact Dermatitis Group Experience, 2009 to 2018. Dermatitis, 2022, 33, 42-50.	1.6	5
5	Contact Dermatitis Associated With Hair Care Products: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2022, 33, 91-102.	1.6	12
6	Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018. Journal of the American Academy of Dermatology, 2022, 86, 818-826.	1.2	7
7	Effect of soak and smear on [14C]-hydrocortisone <i>in vitro</i> human skin percutaneous penetration. Journal of Dermatological Treatment, 2022, 33, 1696-1702.	2.2	1
8	Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. Journal of the American Academy of Dermatology, 2022, 87, 1014-1023.	1.2	6
9	Efficacy of water skin decontamination in vivo in humans: A systematic review. Journal of Applied Toxicology, 2022, 42, 346-359.	2.8	12
10	Patch Test Reactions Associated With Topical Medications: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001–2018). Dermatitis, 2022, 33, 144-154.	1.6	2
11	Photopatch test results of the North American contact dermatitis group, 1999â€2009. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 288-291.	1.5	9
12	Efficacy of waterâ€only or soap and water skin decontamination of chemical warfare agents or simulants using in vitro human models: A systematic review. Journal of Applied Toxicology, 2022, 42, 930-941.	2.8	7
13	How many skin barriers haveth we: Percutaneous egression of ions?. Skin Research and Technology, 2022, 28, 382-387.	1.6	4
14	Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001–2016. Archives of Dermatological Research, 2022, 314, 857-867.	1.9	7
15	Regional variation in percutaneous absorption in <i>in vitro</i> human models: a systematic review. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2022, 25, 97-112.	6.5	2
16	Occupational Contact Dermatitis in Dental Personnel: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001 to 2018. Dermatitis, 2022, 33, 80-90.	1.6	6
17	A review of the efficacy of easily accessible dry decontaminants for human chemical contamination. Journal of Applied Toxicology, 2022, , .	2.8	0
18	Percutaneous egression: What do we know?. Skin Pharmacology and Physiology, 2022, , .	2.5	0

#	Article	IF	CITATIONS
19	Flowâ€through versus static in vitro percutaneous penetration at 50 years: Possible relevance for bioequivalence. Skin Research and Technology, 2022, 28, 540-543.	1.6	4
20	Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. Journal of the American Academy of Dermatology, 2022, 87, 1033-1041.	1.2	4
21	Dose response effect of chemical surface concentration on percutaneous penetration in human: In vivo + in vitro. Regulatory Toxicology and Pharmacology, 2022, 132, 105186.	2.7	2
22	Lanolin Allergic Reactions: North American Contact Dermatitis Group Experience, 2001 to 2018. Dermatitis, 2022, Publish Ahead of Print, .	1.6	2
23	Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. Journal of the American Academy of Dermatology, 2021, 85, 1446-1455.	1.2	16
24	Hair dyes: a systematic review of pertinent in vivo human studies. Archives of Dermatological Research, 2021, 313, 509-516.	1.9	2
25	Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016. Journal of the American Academy of Dermatology, 2021, 84, 953-964.	1.2	16
26	Percutaneous absorption of chemicals from fabric (textile). Journal of Applied Toxicology, 2021, 41, 194-202.	2.8	5
27	Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 977-988.	1.2	6
28	Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 989-999.	1.2	8
29	Effect of superabsorbent polymers (SAP) and metal organic frameworks (MOF) wiping sandwich patch on human skin decontamination and detoxification in vitro. Toxicology Letters, 2021, 337, 7-17.	0.8	5
30	Currently relevant p-phenylenediamine patch test reactions associated with hair dye and nonscalp anatomic areas: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 2001 to 2016. Journal of the American Academy of Dermatology, 2021, 84, e175-e177.	1.2	1
31	Changes in Chinese patch testing practices over 13 years: Updated crossâ€sectional survey and possible international implications. Contact Dermatitis, 2021, 84, 159-165.	1.4	0
32	Patch Testing With Carmine 2.5% in Petrolatum by the North American Contact Dermatitis Group, 2011–2012. Dermatitis, 2021, 32, 94-100.	1.6	2
33	The 21-day cumulative irritation assay in man: a half-century summary and re-evaluation. Cutaneous and Ocular Toxicology, 2021, 40, 61-65.	1.3	3
34	Optimization of psoriasis mouse models. Journal of Pharmacological and Toxicological Methods, 2021, 108, 107054.	0.7	5
35	North American Contact Dermatitis Group Patch Test Results: 2017–2018. Dermatitis, 2021, 32, 111-123.	1.6	78
36	Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001–2016. Contact Dermatitis, 2021, 85, 46-57.	1.4	6

#	Article	IF	CITATIONS
37	Prevalence and Trend of Allergen Sensitization in Adults and Children with Atopic Dermatitis Referred for Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2853-2866.e14.	3.8	9
38	Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994–2018. Dermatitis, 2021, 32, 256-266.	1.6	2
39	Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018. Contact Dermatitis, 2021, 85, 285-296.	1.4	7
40	Contact dermatitis in music professionals referred for patch testing: North <scp>American</scp> Contact Dermatitis Group data, 1996–2018. Contact Dermatitis, 2021, 85, 359-362.	1.4	0
41	Draize human repeat insult patch test (HRIPT): Seven decades of pitfalls and progress. Regulatory Toxicology and Pharmacology, 2021, 121, 104867.	2.7	6
42	Effect of scratching and friction on human skin in vivo. Skin Research and Technology, 2021, 27, 1049-1056.	1.6	4
43	Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: <scp>N</scp> orth <scp>A</scp> merican <scp>C</scp> ontact <scp>D</scp> ermatitis <scp>G</scp> roup data, 2001â€2016. Contact Dermatitis, 2021, 85, 435-445.	1.4	3
44	Patch Testing During Immunosuppressive Therapy: A Systematic Review. Dermatitis, 2021, 32, 365-374.	1.6	18
45	Relating transdermal delivery plasma pharmacokinetics with in vitro permeation test (IVPT) findings using diffusion and compartment-in-series models. Journal of Controlled Release, 2021, 334, 37-51.	9.9	7
46	Efficacy of soap and water based skin decontamination using in vivo animal models: a systematic review. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2021, 24, 325-336.	6.5	12
47	Efficacy of water-based skin decontamination of occupational chemicals using <i>in vitro</i> human skin models: a systematic review. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2021, 24, 337-353.	6.5	7
48	Contact Urticaria. Immunology and Allergy Clinics of North America, 2021, 41, 467-480.	1.9	9
49	Erythromycin dermal delivery by MoS2 nanoflakes. Journal of Pharmaceutical Investigation, 2021, 51, 691-700.	5.3	8
50	Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System. AAPS PharmSciTech, 2021, 22, 215.	3.3	1
51	Patients with patch test reactions associated with eye care products: Retrospective analysis of <scp>N</scp> orth <scp>A</scp> merican contact dermatitis group data, <scp>2001</scp> â€ <scp>2018</scp> . Contact Dermatitis, 2021, 85, 712-715.	1.4	2
52	Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
53	Patch Testing to Ethylhexylglycerin. Dermatitis, 2021, Publish Ahead of Print, .	1.6	0
54	Patch Testing With Tocopherol and Tocopherol Acetate: The North American Contact Dermatitis Group Experience, 2001 to 2016. Dermatitis, 2021, 32, 308-318.	1.6	3

#	Article	IF	Citations
55	Comparative efficacy of Reactive Skin Decontamination Lotion (RSDL): A systematic review. Toxicology Letters, 2021, 349, 109-114.	0.8	3
56	Ability of mathematical models to predict human in vivo percutaneous penetration of steroids. Regulatory Toxicology and Pharmacology, 2021, 126, 105041.	2.7	4
57	Follicular pathway role in chemical warfare simulants percutaneous penetration. Journal of Applied Toxicology, 2021, 41, 964-971.	2.8	8
58	Percutaneous Absorption of Sunscreen Filters: Review of Issues and Challenges. Current Problems in Dermatology, 2021, 55, 188-202.	0.7	0
59	Positive Patch Test Reactions to Carba Mix and Thiuram Mix: The North American Contact Dermatitis Group Experience (1994–2016). Dermatitis, 2021, 32, 173-184.	1.6	7
60	Can We Separate Oral Lichen Planus from Allergic Contact Dermatitis and Should We Patch Test? A Systematic Review of Chronic Oral Lichenoid Lesions. Dermatitis, 2021, 32, 144-150.	1.6	6
61	Patch Testing of Mercaptobenzothiazole and Mercapto Mix: The North American Contact Dermatitis Group Experience, 1994–2016. Dermatitis, 2021, 32, 232-244.	1.6	2
62	Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis. JAMA Dermatology, 2021, 157, 1456.	4.1	5
63	Identifying and Treating Ocular Manifestations in Psoriasis. American Journal of Clinical Dermatology, 2021, , 1.	6.7	1
64	Efficacy of soap and waterâ€based skin decontamination using in vitro animal models: A systematic review. Journal of Applied Toxicology, 2021, , .	2.8	2
65	Allergic reactions to tattoos: Retrospective analysis of North American Contact Dermatitis Group data, 2001-2016. Journal of the American Academy of Dermatology, 2020, 82, e61-e62.	1.2	6
66	Sensitive Skin Syndrome: AnÂUpdate. American Journal of Clinical Dermatology, 2020, 21, 401-409.	6.7	23
67	Patch test in Chinese in Shanghai with cosmetic allergy to cosmetic series and products. Journal of Cosmetic Dermatology, 2020, 19, 2086-2092.	1.6	6
68	Facial Dermatitis in Male Patients Referred for Patch Testing. JAMA Dermatology, 2020, 156, 79.	4.1	16
69	Evaluation of Patch Test Findings in Patients With Anogenital Dermatitis. JAMA Dermatology, 2020, 156, 85.	4.1	11
70	Effects of anatomical location on <i>inÂvivo</i> percutaneous penetration in man. Cutaneous and Ocular Toxicology, 2020, 39, 213-222.	1.3	17
71	Organic compounds percutaneous penetration in vivo in man: Relationship to mathematical predictive model. Regulatory Toxicology and Pharmacology, 2020, 112, 104614.	2.7	9
72	Allergic Contact Dermatitis to Components of Wearable Adhesive Health Devices. Dermatitis, 2020, 31, 283-286.	1.6	18

#	Article	IF	Citations
73	Editorial: Pathophysiology of Sensitive Skin. Frontiers in Medicine, 2020, 7, 159.	2.6	1
74	Contact Dermatitis Associated With Nail Care Products: Retrospective Analysis of North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2020, 31, 191-201.	1.6	19
75	Experimental design in formulation optimization of vitamin K1 oxide-loaded nanoliposomes for skin delivery. International Journal of Pharmaceutics, 2020, 579, 119136.	5.2	16
76	Lateral spread and percutaneous penetration: An overview. International Journal of Pharmaceutics, 2020, 588, 119765.	5.2	0
77	Tandem repeated irritation test (TRIT) studies and clinical relevance: Post 2006. Cutaneous and Ocular Toxicology, 2019, 38, 309-314.	1.3	1
78	Sebo-pharmacokinetics: a proposed percutaneous sebum egression method. Journal of Dermatological Treatment, 2019, 30, 189-193.	2.2	1
79	Development of hydrophilic gels containing coenzyme Q ₁₀ -loaded liposomes: characterization, stability and rheology measurements. Drug Development and Industrial Pharmacy, 2019, 45, 43-54.	2.0	16
80	Contact dermatitis to Dermabond Advance®. Australasian Journal of Dermatology, 2019, 60, 63-64.	0.7	5
81	Skin toxicity of topically applied nanoparticles. Therapeutic Delivery, 2019, 10, 383-396.	2.2	33
82	Percutaneous penetration of drugs applied in transdermal delivery systems: an in vivo based approach for evaluating computer generated penetration models. Regulatory Toxicology and Pharmacology, 2019, 108, 104428.	2.7	16
83	Dermatotoxicology of microneedles (MNs) in man. Biomedical Microdevices, 2019, 21, 66.	2.8	19
84	Parabens. Dermatitis, 2019, 30, 3-31.	1.6	105
85	Patients with negative patch tests: Retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016. Journal of the American Academy of Dermatology, 2019, 80, 1618-1629.	1.2	11
86	Safety equipment: When protection becomes a problem. Contact Dermatitis, 2019, 81, 130-132.	1.4	20
87	Epidemiology of nickel sensitivity: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data 1994-2014. Journal of the American Academy of Dermatology, 2019, 80, 701-713.	1.2	25
88	Occupationally Related Nickel Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 1998–2016. Dermatitis, 2019, 30, 306-313.	1.6	15
89	Pharmacogenomics/updated for precision medicine in dermatology. Journal of Dermatological Treatment, 2019, 30, 410-413.	2.2	4
90	Should we instruct patients to rub topical agents into skin? The evidence. Journal of Dermatological Treatment, 2019, 30, 328-332.	2.2	7

#	Article	IF	Citations
91	Undeclared formaldehyde levels in patient consumer products: formaldehyde test kit utility. Cutaneous and Ocular Toxicology, 2019, 38, 112-117.	1.3	16
92	Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. Journal of Cosmetic Science, 2019, 70, 299-312.	0.1	1
93	Epidemiology of pediatric nickel sensitivity: Retrospective review of North American Contact Dermatitis Group (NACDG) data 1994-2014. Journal of the American Academy of Dermatology, 2018, 79, 664-671.	1.2	34
94	Possible role of regional variation in allergic contact dermatitis: case report. Contact Dermatitis, 2018, 78, 228-229.	1.4	5
95	Combined use of nanocarriers and physical methods for percutaneous penetration enhancement. Advanced Drug Delivery Reviews, 2018, 127, 58-84.	13.7	76
96	Binding affinity and decontamination of dermal decontamination gel to model chemical warfare agent simulants. Journal of Applied Toxicology, 2018, 38, 724-733.	2.8	9
97	In vitro human skin permeation and decontamination of 2-chloroethyl ethyl sulfide (CEES) using Dermal Decontamination Gel (DDGel) and Reactive Skin Decontamination Lotion (RSDL). Toxicology Letters, 2018, 291, 86-91.	0.8	16
98	Dermalâ \in epidermal separation methods: research implications. Archives of Dermatological Research, 2018, 310, 1-9.	1.9	26
99	North American Contact Dermatitis Group Patch Test Results: 2015–2016. Dermatitis, 2018, 29, 297-309.	1.6	230
100	In vitro human skin permeation and decontamination of diisopropyl methylphosphonate (DIMP) using Dermal Decontamination Gel (DDGel) and Reactive Skin Decontamination Lotion (RSDL) at different timepoints. Toxicology Letters, 2018, 299, 118-123.	0.8	13
101	Stratum corneum substantivity: drug development implications. Archives of Dermatological Research, 2018, 310, 537-549.	1.9	8
102	Relapsing polyisoprene glove allergic contact dermatitis: Another call for more complete glove package label declaration. Contact Dermatitis, 2018, 79, 242-243.	1.4	3
103	Dorsal hand skin hyperpigmentation following oral olanzapine (Zyprexa) use. Contact Dermatitis, 2018, 79, 254-255.	1.4	1
104	Mesoporous silica nanoparticles for enhanced lidocaine skin delivery. International Journal of Pharmaceutics, 2018, 550, 325-332.	5.2	40
105	RNA Loading on Nano-Structured Hyperbranched \hat{l}^2 -Cyclodextrin. Avicenna Journal of Medical Biotechnology, 2018, 10, 15-21.	0.3	1
106	Terbinafine-induced lichenoid drug eruption. Cutaneous and Ocular Toxicology, 2017, 36, 101-103.	1.3	14
107	Antifungal ME1111 <i>in vitro</i> human onychopharmacokinetics. Drug Development and Industrial Pharmacy, 2017, 43, 22-29.	2.0	8
108	Fullerene nanoparticle in dermatological and cosmetic applications. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1071-1087.	3.3	105

#	Article	IF	Citations
109	Vehicle effects on human stratum corneum absorption and skin penetration. Toxicology and Industrial Health, 2017, 33, 416-425.	1.4	22
110	Confocal laser scanning microscopy to estimate nanoparticles' human skin penetration in vitro. International Journal of Nanomedicine, 2017, Volume 12, 8035-8041.	6.7	22
111	Ultraviolet A Enhances Cathepsin L Expression and Activity via JNK Pathway in Human Dermal Fibroblasts. Chinese Medical Journal, 2016, 129, 2853-2860.	2.3	14
112	Effects of soap–water wash on human epidermal penetration. Journal of Applied Toxicology, 2016, 36, 997-1002.	2.8	26
113	Depthâ€dependent stratum corneum permeability in human skin <i>in vitro</i> . Journal of Applied Toxicology, 2016, 36, 1207-1213.	2.8	11
114	Reliability of dispensers for patch testing. Contact Dermatitis, 2016, 74, 382-383.	1.4	1
115	Recent knowledge: Concepts of dermal absorption in relation to skin decontamination. Journal of Applied Toxicology, 2016, 36, 5-9.	2.8	4
116	Proposed human stratum corneum water domain in chemical absorption. Journal of Applied Toxicology, 2016, 36, 991-996.	2.8	14
117	Improved Voriconazole Topical Delivery by Nanoparticles (Minireview). Pharmaceutical Chemistry Journal, 2016, 50, 76-79.	0.8	11
118	Ethnic and socioeconomic disparities in dermatology. Journal of Dermatological Treatment, 2016, 27, 290-291.	2.2	13
119	Percutaneous penetration and pharmacodynamics: Wash-in and wash-off of sunscreen and insect repellent. Journal of Dermatological Treatment, 2016, 27, 11-18.	2.2	15
120	The effect of volatility on percutaneous absorption. Journal of Dermatological Treatment, 2016, 27, 5-10.	2.2	6
121	Jewellery: alloy composition and release of nickel, cobalt and lead assessed with the <scp>EU</scp> synthetic sweat method. Contact Dermatitis, 2015, 73, 231-238.	1.4	34
122	Emerging therapies for the treatment of ungual onychomycosis. Drug Development and Industrial Pharmacy, 2015, 41, 1575-1581.	2.0	22
123	"Open Sourceâ€â€"Based Engineered Human Tissue Models: A New Gold Standard for Nonanimal Testing Through Openness, Transparency, and Collaboration, Promoted by the ALEXANDRA Association. Applied in Vitro Toxicology, 2015, 1, 5-9.	1.1	9
124	Novel drug delivery strategies for improving econazole antifungal action. International Journal of Pharmaceutics, 2015, 495, 599-607.	5.2	61
125	Evaluating clinical trial design: systematic review of randomized vehicle-controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Archives of Dermatological Research, 2015, 307, 757-766.	1.9	10
126	Discontinued dermatological drugs in 2014. Expert Opinion on Investigational Drugs, 2015, 24, 1483-1491.	4.1	2

#	Article	IF	Citations
127	Shaving effects on percutaneous penetration: clinical implications. Cutaneous and Ocular Toxicology, 2015, 34, 335-343.	1.3	6
128	Effect of massage on percutaneous penetration and skin decontamination: man and animal. Cutaneous and Ocular Toxicology, 2015, 35, 1-4.	1.3	7
129	Role of sebaceous glands in inflammatory dermatoses. Journal of the American Academy of Dermatology, 2015, 73, 856-863.	1.2	99
130	Ultraviolet A-Induced Cathepsin K Expression Is Mediated via MAPK/AP-1 Pathway in Human Dermal Fibroblasts. PLoS ONE, 2014, 9, e102732.	2.5	34
131	Active ingredients against human epidermal aging. Ageing Research Reviews, 2014, 15, 100-115.	10.9	100
132	Using skin for drug delivery and diagnosis in the critically ill. Advanced Drug Delivery Reviews, 2014, 77, 40-49.	13.7	22
133	Adhesive tape technique to enhance potassium hydroxide diagnosis of occult fungal infections. Journal of the American Academy of Dermatology, 2014, 70, e103.	1.2	0
134	Dermal exposure to methamphetamine hydrochloride contaminated residential surfaces II. Skin surface contact and dermal transfer relationship. Food and Chemical Toxicology, 2014, 66, 1-6.	3.6	10
135	A pilot study demonstrating a nonâ€invasive method for the measurement of protein turnover in skin disorders: application to psoriasis. Clinical and Translational Medicine, 2013, 2, 12.	4.0	20
136	Characteristics of the Aging Skin. Advances in Wound Care, 2013, 2, 5-10.	5.1	321
137	<i>Ex vivo</i> calcium percutaneous eggression in normal and tape-stripped human skin. Cutaneous and Ocular Toxicology, 2012, 31, 1-6.	1.3	6
138	Pharmacokinetics of [14C]-atrazine in rhesus monkeys, single-dose intravenous and oral administration. Toxicological and Environmental Chemistry, 2011, 93, 370-382.	1.2	4
139	In-vitro Skin Pharmacokinetics of Acitretin: Percutaneous Absorption Studies in Intact and Modified Skin from Three Different Species using Different Receptor Solutions. Journal of Pharmacy and Pharmacology, 2011, 43, 836-840.	2.4	19
140	Occlusive therapy in atopic dermatitis: Overview. Journal of Dermatological Treatment, 2010, 21, 62-72.	2.2	34
141	Toxicologic implications of cutaneous barriers: a molecular, cellular, and anatomical overview. Journal of Applied Toxicology, 2009, 29, 551-559.	2.8	14
142	Effects and Uses of Occlusion on Human Skin: An Overview. Cutaneous and Ocular Toxicology, 2005, 24, 91-104.	1.3	5
143	Selegiline Transdermal System (STS): Assessments of Dermal Safety in Human. Cutaneous and Ocular Toxicology, 2005, 23, 179-187.	0.3	3
144	Selegiline Transdermal System (STS): Preclinical Assays of Dermal Safety. Cutaneous and Ocular Toxicology, 2005, 23, 173-178.	0.3	1

#	Article	IF	CITATIONS
145	Gender Differences in the Pharmacokinetics of Oral Dermatologic Medications. Cutaneous and Ocular Toxicology, 2005, 23, 119-133.	0.3	5
146	Estrogen and Skin. American Journal of Clinical Dermatology, 2001, 2, 143-150.	6.7	181
147	Electronic Monitoring in Medication Adherence Measurement. American Journal of Clinical Dermatology, 2001, 2, 7-12.	6.7	42
148	Relationship Between Systemic Corticosteroids and Osteonecrosis. American Journal of Clinical Dermatology, 2001, 2, 377-388.	6.7	45
149	Skin occlusion and irritant and allergic contact dermatitis: an overview. Contact Dermatitis, 2001, 44, 201-206.	1.4	98
150	Allergic contact dermatitis from cycloaliphatic epoxide in jet aviation hydraulic fluid. Contact Dermatitis, 2001, 45, 56-56.	1.4	14
151	Occupational allergic contact dermatitis from methyl chloroform (1,1,1-trichloroethane)?. Contact Dermatitis, 2001, 45, 107-107.	1.4	3
152	Sea water or its components alter experimental irritant dermatitis in man. Skin Research and Technology, 2001, 7, 36-39.	1.6	25
153	Physical and physiological effects of stratum corneum tape stripping. Skin Research and Technology, 2001, 7, 40-48.	1.6	177
154	Epidermal cytokines in murine cutaneous irritant responses. Journal of Applied Toxicology, 2000, 20, 335-341.	2.8	72
155	Skin hyporeactivity in relation to patch testing. Contact Dermatitis, 2000, 42, 1-4.	1.4	11
156	Use tests: ROAT (repeated open application test)/PUT (provocative use test): an overview. Contact Dermatitis, 2000, 43, 1-3.	1.4	87
157	Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opinion on Pharmacotherapy, 2000, 1, 467-473.	1.8	11
158	Influence of evaporation and solvent mixtures on the absorption of toluene and <italic>n</italic> -butanol in human skin in vitro. Annals of Occupational Hygiene, 2000, , .	1.9	17
159	Squamometry: an evaluation method for a barrier protectant (tannic acid). Contact Dermatitis, 1999, 40, 189-191.	1.4	15
160	In vivo nickel allergic contact dermatitis: human model for topical therapeutics. Contact Dermatitis, 1999, 40, 205-208.	1.4	11
161	Occupational contact dermatitis caused by polyfunctional aziridine crosslinker: duct tubing for airconditioning. Contact Dermatitis, 1999, 41, 163-163.	1.4	6
162	Active sensitization to sodium metabisulfite in hydrocortisone cream. Contact Dermatitis, 1999, 41, 166-167.	1.4	42

#	Article	IF	CITATIONS
163	Putative skin-protective formulations in preventing and/or inhibiting experimentally-produced irritant and allergic contact dermatitis. Contact Dermatitis, 1999, 41, 190-192.	1.4	18
164	Allergic contact dermatitis from tropicamide ophthalmic solution. Contact Dermatitis, 1999, 41, 47-48.	1.4	15
165	Influence of surfactant mixtures on intercellular lipid fluidity and skin barrier function. Skin Research and Technology, 1999, 5, 96-101.	1.6	29
166	How irritant is water? An overview. Contact Dermatitis, 1999, 41, 311-314.	1.4	137
167	Human cadaver skin viability for in vitro percutaneous absorption: storage and detrimental effects of heat-separation and freezing. Pharmaceutical Research, 1998, 15, 82-84.	3.5	82
168	In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharmaceutical Research, 1998, 15, 988-992.	3.5	27
169	Stratum corneum thickness and apparent water diffusivity: facile and noninvasive quantitation in vivo. Pharmaceutical Research, 1998, 15, 492-494.	3. 5	57
170	Cigarette smoking, cutaneous vasculature and tissue oxygen: an overview. Skin Research and Technology, 1998, 4, 1-8.	1.6	11
171	Sodium lauiyl sulphate damaged skin in vivo in man: a water barrier repair model. Skin Research and Technology, 1998, 4, 24-27.	1.6	6
172	Open application assay in investigation of subclinical irritant dermatitis induced by sodium lauryl sulfate (SLS) in man: advantage of squamometry. Skin Research and Technology, 1998, 4, 244-250.	1.6	25
173	Metal polisher as a putative cause of allergic contact dermatitis from ethylenediamine. Contact Dermatitis, 1998, 38, 116-116.	1.4	3
174	Latex glove facial allergic contact dermatitis without hand manifestations. Contact Dermatitis, 1998, 38, 118-118.	1.4	3
175	Evaluating skin-protective materials against contact irritants and allergens Contact Dermatitis, 1998, 38, 155-158.	1.4	77
176	Eyeglass allergic contact dermatitis. Contact Dermatitis, 1998, 39, 1-3.	1.4	26
177	In vivo percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in humans. Biological Trace Element Research, 1998, 66, 101-109.	3.5	12
178	In vitro percutaneous absorption of boron as boric acid, borax, and disodium octaborate tetrahydrate in human skin. Biological Trace Element Research, 1998, 66, 111-120.	3.5	5
179	Stripped skin model to predict irritation potential of topical agents <i>in vivo</i> in humans. International Journal of Dermatology, 1998, 37, 386-389.	1.0	18
180	In Vivo Percutaneous Absorption of Boric Acid, Borax, and Disodium Octaborate Tetrahydrate in Humans Compared to in Vitro Absorption in Human Skin from Infinite and Finite Doses. Toxicological Sciences, 1998, 45, 42-51.	3.1	46

#	Article	IF	CITATIONS
181	Irritant contact dermatitis. Postgraduate Medicine, 1998, 103, 199-213.	2.0	15
182	Patterns of Hyaluronan Staining Are Modified by Fixation Techniques. Journal of Histochemistry and Cytochemistry, 1997, 45, 1157-1163.	2.5	124
183	Acute irritant contact dermatitis: recovery time in man. Contact Dermatitis, 1997, 36, 285-290.	1.4	55
184	Induction of contact sensitization to monotertiary butyl hydroquinone. Contact Dermatitis, 1997, 37, 92-93.	1.4	1
185	RÃ1e of ear piercing in metal allergic contact dermatitis. Contact Dermatitis, 1997, 36, 233-236.	1.4	90
186	Patch test materials for mercury allergic contact dermatitis. Contact Dermatitis, 1997, 36, 237-239.	1.4	20
187	Patch testing versus history in poison ivy/oak dermatitis. Contact Dermatitis, 1997, 36, 226-226.	1.4	2
188	Pseudo flautist's lip: allergic contact cheilitis from geraniol. Contact Dermatitis, 1997, 37, 39-39.	1.4	7
189	Piperazine diacrylamide allergic contact dermatitis. Contact Dermatitis, 1997, 37, 300-301.	1.4	12
190	Allergic contact dermatitis from oxidizedd-limonene. Contact Dermatitis, 1997, 37, 308-308.	1.4	19
191	The provocative use test (PUT) [repeated open application test (ROAT)] in topical corticosteroid allergic contact dermatitis. Contact Dermatitis, 1997, 37, 309-311.	1.4	5
192	Trimellitic anhydride-sensitive mouse as an animal model for contact urticaria., 1997, 17, 357-360.		23
193	Spacial variability of basal skin chromametry on the ventral forearm of healthy volunteers. Archives of Dermatological Research, 1996, 288, 774-777.	1.9	28
194	So-called marginal patch test irritation: attempt at a predictive assay. Contact Dermatitis, 1996, 35, 50-51.	1.4	3
195	Effect of barrier creams: human skin in vivo. Contact Dermatitis, 1996, 35, 92-96.	1.4	73
196	Airborne contact dermatitis from metaproterenol in a respiratory therapist. Contact Dermatitis, 1996, 35, 317-318.	1.4	14
197	Allergic contact dermatitis from norflurazon (Predict \hat{A}°). Contact Dermatitis, 1996, 35, 369-370.	1.4	3
198	Spacial variability of basal skin chromametry on the ventral forearm of healthy volunteers. Archives of Dermatological Research, 1996, 288, 774-777.	1.9	9

#	Article	IF	CITATIONS
199	Methods for Assessing Percutaneous Absorption. ATLA Alternatives To Laboratory Animals, 1996, 24, 81-106.	1.0	145
200	The sodium lauryl sulfate model: an overview. Contact Dermatitis, 1995, 33, 1-7.	1.4	142
201	Surfactants and experimental irritant contact dermatitis. Contact Dermatitis, 1995, 33, 217-225.	1.4	204
202	Contact urticaria from polyurethane-membrane hypoallergenic gloves. Contact Dermatitis, 1995, 33, 200-201.	1.4	11
203	Contact urticaria from cucumber pickle and strawberry. Contact Dermatitis, 1995, 32, 173-174.	1.4	24
204	Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Contact Dermatitis, 1995, 33, 289-298.	1.4	81
205	Allergic contact cheilitis. Contact Dermatitis, 1995, 33, 365-370.	1.4	44
206	Baseline transepidermal water loss in patients with acute and healed irritant contact dermatitis. Contact Dermatitis, 1995, 33, 371-374.	1.4	30
207	Effect of age and sex on the elicitation of irritant contact dermatitis. Contact Dermatitis, 1994, 30, 257-264.	1.4	51
208	Study of cumulative irritant contact dermatitis in man utilizing open application on subclinically irritated skin. Contact Dermatitis, 1994, 30, 271-273.	1.4	24
209	Topical application of artesunate on guinea pig allergic contact dermatitis. Contact Dermatitis, 1994, 30, 280-282.	1.4	22
210	Effect of surfactant mixtures on irritant contact dermatitis potential in man: sodium lauroyl glutamate and sodium lauryl sulphate. Contact Dermatitis, 1994, 30, 205-209.	1.4	34
211	Alcohol dermatitis: allergic contact dermatitis and contact urticaria syndrome. Contact Dermatitis, 1994, 30, 1-6.	1.4	106
212	Propylene glycol dermatitis: reâ€evaluation of an old problem. Contact Dermatitis, 1994, 31, 236-241.	1.4	88
213	Transdermal lontophoresis. Clinical Pharmacokinetics, 1994, 26, 327-334.	3.5	22
214	An in Vivo Correlation with Three in Vitro Assays to Assess Skin Irritation Potential. Cutaneous and Ocular Toxicology, 1994, 13, 171-183.	0.3	12
215	Equation for conversion of transepidermal water loss (TEWL) to a common reference temperature: what is the slope?. Contact Dermatitis, 1993, 29, 280-281.	1.4	28
216	Intradermal testing in the diagnosis of allergic contact dermatitis. Contact Dermatitis, 1993, 29, 1-5.	1.4	44

#	Article	IF	CITATIONS
217	Influence of skin irritants on percutaneous absorption. Pharmaceutical Research, 1993, 10, 1756-1759.	3.5	15
218	Skin Penetration and Metabolism: Comparative Evaluation of Skin Equivalent, Cell Culture, and Human Skin. Cutaneous and Ocular Toxicology, 1993, 12, 129-138.	0.3	7
219	Percutaneous absorption of PCBs from soil: In vivo rhesus monkey, in vitro human skin, and binding to powdered human stratum corneum. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1993, 39, 375-382.	2.3	46
220	In vivo percutaneous absorption and skin decontamination of alachlor in rhesus monkey. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1992, 36, 1-12.	2.3	18
221	Dermal absorption of the phenoxy herbicide 2,4â€D dimethylamine in humans: Effect of DEET and anatomic site. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1992, 36, 241-250.	2.3	37
222	Influence of area of application of allergen on sensitization in contact dermatitis. Contact Dermatitis, 1992, 27, 281-286.	1.4	60
223	ISSUES IN MEASURING PERCUTANEOUS ABSORPTION OF TOPICAL CORTICOSTEROIDS. International Journal of Dermatology, 1992, 31, 21-25.	1.0	30
224	High-performance liquid chromatography determination of acitretin in plasma and its application to a pharmacokinetic study in human subjects. Pharmaceutical Research, 1992, 09, 1365-1369.	3.5	7
225	In Vitro Percutaneous Absorption of Cadmium from Water and Soil into Human Skin. Toxicological Sciences, 1992, 19, 1-5.	3.1	12
226	In vivo transcutaneous penetration of nicotinates and sensitive skin. Contact Dermatitis, 1991, 25, 35-38.	1.4	38
227	Irritation factors of sodium hypochlorite solutions in human skin. Contact Dermatitis, 1990, 23, 316-324.	1.4	24
228	Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate. Pharmaceutical Research, 1990, 07, 1298-1301.	3.5	2
229	Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharmaceutical Research, 1990, 07, 1320-1324.	3.5	93
230	Transepidermal Potassium Ion, Chloride Ion, and Water Flux across Delipidized and Cellophane Tape-Stripped Skin. Dermatology, 1990, 180, 66-68.	2.1	32
231	Dermal absorption of the phenoxy herbicides 2,4â€D, 2,4â€D amine, 2,4â€D isooctyl, and 2,4,5â€T in rabbits, rats rhesus monkeys, and humans: A crossâ€species comparison. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1990, 29, 237-245.	5, 2.3	50
232	Percutaneous absorption and skin decontamination of PCBS: In vitro studies with human skin and in vivo studies in the rhesus monkey. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1990, 31, 235-246.	2.3	37
233	The Practical Use of Methotrexate in Psoriasis. Drugs, 1990, 40, 697-712.	10.9	20
234	Percutaneous Penetration and Mass Balance Accountability: Technique and Implications for Dermatology. Cutaneous and Ocular Toxicology, 1989, 8, 439-451.	0.3	10

#	Article	IF	Citations
235	The effect of aging on percutaneous absorption in man. Journal of Pharmacokinetics and Pharmacodynamics, 1989, 17, 617-630.	0.6	141
236	Post-application occlusion substantially increases the irritant response of the skin to repeated short-term sodium lauryl sulfate (SLS) exposure. Contact Dermatitis, 1989, 21, 335-338.	1.4	66
237	Differences in the Biochemical Activity in Hairless Mouse Skin and Other Organs after Systemic and Topical Methotrexate Treatment. Journal of Dermatology, 1989, 16, 475-479.	1.2	5
238	Mass balance and dose accountability in percutaneous absorption studies: development of a nonocclusive application system. Pharmaceutical Research, 1988, 05, 313-315.	3.5	20
239	TREATMENT OF PSORIASIS WITH 6-THIOGUANINE. Australasian Journal of Dermatology, 1988, 29, 163-167.	0.7	17
240	Percutaneous absorption of hydroquinone in humans: Effect of 1â€dodecylazacycloheptanâ€2â€one (azone) and the 2â€ethylhexyl ester of 4â€(dimethylamino)benzoic acid (escalol 507). Journal of Toxicology and Environmental Health - Part A: Current Issues, 1988, 24, 279-289.	2.3	23
241	In vivo and in vitro absorption and binding to powdered stratum corneum as methods to evaluate skin absorption of environmental chemical contaminants from ground and surface water. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1987, 21, 367-374.	2.3	37
242	Skin absorption from patch test systems. Contact Dermatitis, 1987, 17, 178-180.	1.4	17
243	Title is missing!. Pharmaceutical Research, 1987, 04, 265-267.	3.5	141
244	A Simplified Disc Technique for Quantitating Mouse DNA, RNA and Protein Synthesis: Circadian Rhythms. Journal of Dermatology, 1986, 13, 108-112.	1.2	2
245	Textile chemical finish dermatitis. Contact Dermatitis, 1986, 14, 1-13.	1.4	64
246	Dyclonine hydrochloride, local anaesthetic allergic contact dermatitis. Contact Dermatitis, 1986, 14, 114-114.	1.4	6
247	The bioavailability of dermatological and other topically administered drugs. Pharmaceutical Research, 1986, 03, 253-262.	3.5	26
248	Benzene levels in ambient air and breath of smokers and nonsmokers in urban and pristine environments. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1986, 18, 567-573.	2.3	51
249	Contact urticaria from diethyl fumarate. Contact Dermatitis, 1985, 12, 139-140.	1.4	27
250	Optical Techniques for Monitoring Cutaneous Microcirculation International Journal of Dermatology, 1985, 24, 88-94.	1.0	31
251	In vivo percutaneous absorption and decontamination of pesticides in humans. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1985, 16, 25-37.	2.3	105
252	Optical Techniques for Monitoring Cutaneous Microcirculation. International Journal of Dermatology, 1985, 24, 88-94.	1.0	1

#	Article	IF	CITATIONS
253	In vivopercutaneous absorption of paraquat from hand, leg, and forearm of humans. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1984, 14, 759-762.	2.3	49
254	Effect of vehicle on elicitation of DNCB contact allergy in the guinea pig. Contact Dermatitis, 1984, 10, 166-169.	1.4	18
255	Flare-up reactions and desensitization from oral dosing in chromate-sensitive guinea pigs. Contact Dermatitis, 1984, 10, 277-279.	1.4	4
256	Allergic contact dermatitis from stearamidoethyl diethylamine phosphate: a cosmetic emulsifier. Contact Dermatitis, 1984, 10, 74-76.	1.4	11
257	True cross-sensitization, false cross-sensitization and otherwise. Contact Dermatitis, 1984, 11, 65-69.	1.4	52
258	Pharmacodynamic measurements of methyl nicotinate percutaneous absorption. Pharmaceutical Research, 1984, 01, 76-81.	3. 5	45
259	Cutaneous cytodestructive potency of lignans. Archives of Dermatological Research, 1982, 274, 9-20.	1.9	18
260	Quantification of the excited skin syndrome (the "angry backâ€) Retesting one patch at a time. Contact Dermatitis, 1982, 8, 78-78.	1.4	23
261	Transepidermal chloride flux through hydrated skin: combination chloride electrode. British Journal of Dermatology, 1981, 105, 39-44.	1.5	11
262	Cumulative irritancy in the guinea Pig from low grade irritant vehicles and the angry skin syndrome. Contact Dermatitis, 1980, 6, 430-434.	1.4	27
263	A comparison of the antimicrobial effect of 0.5% chlorhexidine (HibistatR) and 70% isopropyl alcohol on hands contaminated with Serratia marcescens. Clinical and Experimental Dermatology, 1980, 5, 197-201.	1.3	26
264	The guinea-pig: an animal model for human skin absorption of hydrocortisone, testosterone and benzoic acid?. British Journal of Dermatology, 1980, 102, 447-453.	1.5	46
265	Role of Teichoic Acid in the Binding of Staphylococcus aureus to Nasal Epithelial Cells. Journal of Infectious Diseases, 1980, 141, 463-465.	4.0	137
266	Allergic Reaction to Drugs Used Topically. Clinical Toxicology, 1980, 16, 415-465.	0.5	14
267	Quantitative microbiology of human vulva. British Journal of Dermatology, 1979, 101, 445-448.	1.5	31
268	Detection of environmental depigmenting substances. Contact Dermatitis, 1979, 5, 201-213.	1.4	58
269	Human cutaneous vulvar reactivity to irritants. Contact Dermatitis, 1979, 5, 375-377.	1.4	101
270	Skin Barrier Properties in the Newborn. Neonatology, 1977, 32, 177-182.	2.0	55

#	ARTICLE	IF	CITATION
271	Bacterial flora in psoriasis. British Journal of Dermatology, 1976, 95, 603-606.	1.5	65
272	Percutaneous Penetration and Disposition of Triclocarban in Man. Archives of Environmental Health, 1975, 30, 7-14.	0.4	31
273	Effect of some irritants on human epidermal mitosis. Contact Dermatitis, 1975, 1, 273-276.	1.4	33
274	THE EFFECT OF OCCULUSIVE AND SEMIUPERMEABLE DRESSINGS ON THE MITOTIC ACTRIVITY OF NORMAL AND WOUDED HUMAN EPIDERMIS. British Journal of Dermatology, 1972, 86, 593-600.	1.5	38
275	The Effect of Perfusion Rate on In Vitro Percutaneous Penetration**From the Division of Dermatology, University of California School of Medicine, San Francisco, California 94122 Journal of Investigative Dermatology, 1969, 53, 264-269.	0.7	45
276	Transepidermal water loss (TEWL): Environment and pollution—A systematic review. Skin Health and Disease, 0, , .	1.5	11